Education
About Us
Working with TipRanks
Follow Us
Revolution Medicines, Inc. (RVMD)
:RVMD
Top Page
Revolution Medicines
(NASDAQ:RVMD)
51Neutral
Positive Factors
Clinical Trials
The addition of two registrational trials for daraxonrasib in earlier lines of PDAC is expected to positively influence the stock.
Financial Position
Revolution ended 2024 with roughly $2.29B in cash and cash equivalents, providing an operational runway through multiple key data catalysts.
Negative Factors
Efficacy Data
The update provided limited visibility into the efficacy profile of the RMC-6236 and RMC-6291 combinations.
Operating Expenses
Revolution recorded a net loss of $1.12 per share—wider than previously estimated due to greater-than-expected operating expenses.
Revolution Medicines (RVMD) vs. S&P 500 (SPY)
Market Cap
$6.25B
Dividend YieldN/A
Average Volume (3M)1.48M
Price to Earnings (P/E)―
Beta (1Y)1.12
Revenue Growth-100.00%
EPS Growth5.49%
CountryUS
Employees534
SectorHealthcare
Sector Strength62
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.57
Shares Outstanding185,913,330
10 Day Avg. Volume1,669,927
30 Day Avg. Volume1,482,052
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)12629.51
Price to Cash Flow (P/CF)-12.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$68.55Price Target Upside98.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Revolution Medicines Business Overview & Revenue Model
Company DescriptionRevolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
How the Company Makes MoneyRevolution Medicines generates revenue primarily through strategic collaborations, research and development partnerships, and milestone payments from other pharmaceutical companies. The company enters into agreements with larger pharmaceutical firms to co-develop and commercialize its drug candidates, often receiving upfront payments, research funding, and future royalties on sales of successfully developed products. Additionally, Revolution Medicines may also benefit from licensing agreements, wherein it grants other companies the rights to use its proprietary technologies or compounds in exchange for licensing fees.
Revolution Medicines Financial Statement Overview
Summary
Revolution Medicines faces significant financial challenges with declining revenues and persistent losses, common in the biotechnology industry due to high R&D costs and long product development cycles. While the balance sheet reflects strong liquidity and low leverage, the cash flow statement highlights the need for efficient cash management to sustain operations.Income Statement
Revolution Medicines shows a declining revenue trend over the past five years, with a significant drop to zero revenue in the most recent year. Margins, including gross profit and net income, are negative, reflecting substantial losses and indicating challenges in achieving profitability.45
Neutral
Balance Sheet
The company has maintained a strong cash position with negative net debt, suggesting adequate liquidity. However, the consistent high levels of net losses are concerning. The debt-to-equity ratio remains low, indicating conservative leverage, which is positive for financial stability.60
Neutral
Cash Flow
Cash flows remain negative with increasing operating and free cash flow deficits, suggesting ongoing challenges in generating positive cash flow from operations. However, substantial financing activities have bolstered cash reserves, which can support operations in the short term.50
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 11.58M | 35.38M | 29.39M | 42.98M |
| Gross Profit | ||||
| 0.00 | 11.58M | 25.72M | 22.06M | -89.27M |
| EBIT | ||||
| -689.52M | -487.19M | -258.28M | -188.01M | -110.70M |
| EBITDA | ||||
| -689.52M | -430.58M | -239.47M | -179.75M | -101.91M |
| Net Income Common Stockholders | ||||
| -600.09M | -436.37M | -248.71M | -179.77M | -108.16M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 2.29B | 1.85B | 644.94M | 577.05M | 440.74M |
| Total Assets | ||||
| 2.56B | 2.06B | 811.93M | 737.99M | 567.40M |
| Total Debt | ||||
| 135.84M | 87.94M | 64.20M | 66.63M | 32.66M |
| Net Debt | ||||
| -407.22M | -608.20M | -97.21M | -41.86M | -71.60M |
| Total Liabilities | ||||
| 293.10M | 235.51M | 126.74M | 135.42M | 92.72M |
| Stockholders Equity | ||||
| 2.27B | 1.83B | 685.19M | 602.57M | 474.68M |
| Cash Flow | Free Cash Flow | |||
| -567.74M | -358.30M | -235.22M | -153.71M | -103.00M |
| Operating Cash Flow | ||||
| -557.44M | -350.57M | -224.40M | -147.18M | -100.06M |
| Investing Cash Flow | ||||
| -554.39M | -342.60M | -24.12M | -142.12M | -234.23M |
| Financing Cash Flow | ||||
| 959.41M | 1.23B | 301.43M | 294.18M | 422.78M |
Revolution Medicines Technical Analysis
Negative
34.60
Price Trends
39.81
Negative
44.20
Negative
44.48
Negative
Market Momentum
-1.21
Positive
28.66
Positive
10.49
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RVMD, the sentiment is Negative. The current price of 34.6 is below the 20-day moving average (MA) of 37.62, below the 50-day MA of 39.81, and below the 200-day MA of 44.48, indicating a bearish trend. The MACD of -1.21 indicates Positive momentum. The RSI at 28.66 is Positive, neither overbought nor oversold. The STOCH value of 10.49 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RVMD.
Revolution Medicines Risk Analysis
Revolution Medicines disclosed 82 risk factors in its most recent earnings report. Revolution Medicines reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Revolution Medicines Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $7.50B | 25.50 | 17.90% | 0.19% | 15.52% | 40.29% | |
68 Neutral | $6.51B | 94.83 | 1.61% | 0.97% | 2.45% | -80.87% | |
55 Neutral | $7.03B | 1.93 | -7.10% | ― | -20.84% | -102.48% | |
52 Neutral | $5.49B | ― | -31.26% | ― | 104.04% | 87.80% | |
51 Neutral | $6.25B | ― | -29.33% | ― | -100.00% | 5.49% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
46 Neutral | $6.28B | ― | 35.68% | ― | 2285.27% | 27.90% |
* Healthcare Sector Average
Performance Comparison
RVMD
Revolution Medicines
32.87
2.73
9.06%
TFX
Teleflex
137.99
-72.34
-34.39%
ENSG
The Ensign Group
133.90
15.34
12.94%
BPMC
Blueprint Medicines
87.11
-3.57
-3.94%
BBIO
BridgeBio Pharma
34.07
5.92
21.03%
ROIV
Roivant Sciences
10.01
-1.50
-13.03%
Revolution Medicines Earnings Call Summary
Earnings Call Date: Feb 26, 2025 | % Change Since: -14.57% | Next Earnings Date: May 12, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in Revolution Medicines' RAS(ON) inhibitor pipeline and a strong financial position to support future operations. However, increased net losses and operating expenses were noted. The overall sentiment leans positive given the advancements in clinical trials and strategic collaborations.Highlights
Strong Financial Position
Revolution Medicines ended the fourth quarter of 2024 with $2.3 billion in cash and investments, including $823 million from an equity offering, projecting funding for operations into the second half of 2027.
Advancements in RAS(ON) Inhibitor Pipeline
Significant progress was made with RAS-focused drugs, reporting compelling monotherapy clinical data, especially with daraxonrasib in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer.
Initiation of Phase III Trials
Commencement of Phase III trials for daraxonrasib in non-small cell lung cancer and PDAC, aiming for substantial enrollment completion in 2025.
Strategic Collaborations
Entered into discovery and clinical collaborations to expand treatment strategies, including a PRMT5 inhibitor with Tango and bispecific antibodies with Aethon Therapeutics.
Lowlights
Increased Net Loss
Net loss for Q4 2024 was $194.6 million, an increase from $161.5 million in Q4 2023, attributed to higher operating expenses due to clinical development program expansions.
Increased R&D and G&A Expenses
R&D expenses rose to $188.1 million in Q4 2024 from $148.5 million in Q4 2023, and G&A expenses increased due to commercial preparation activities and personnel-related expenses.
Company Guidance
During the Revolution Medicines Q4 2024 earnings call, significant guidance was provided for the upcoming year. The company reported a strong financial position with $2.3 billion in cash and investments, projecting this to fund operations into the second half of 2027. Key priorities for 2025 include executing pivotal trials for daraxonrasib in metastatic pancreatic cancer and non-small cell lung cancer, with enrollment expected to substantially complete this year for a data readout in 2026. The company plans to initiate a first-line metastatic pancreatic cancer trial with daraxonrasib and chemotherapy and is designing a registrational trial for daraxonrasib in resectable pancreatic cancer as an adjuvant treatment. Additionally, Revolution Medicines aims to generate data to inform development priorities for elironrasib and zoldonrasib, with potential pivotal trials anticipated for 2026. The company expects a GAAP net loss between $840 million and $900 million for 2025, driven by increased expenses from clinical development expansions and commercial preparations.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.